Home / Business and Economy / Vertex Buys Crinetics for $10 Billion in Rare Disease Push
Vertex Buys Crinetics for $10 Billion in Rare Disease Push
7 Jul
Summary
- Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals for $10 billion.
- The deal aims to expand Vertex's reach into endocrinology medicines.
- Crinetics shares saw a 102% premium in the acquisition price.
Vertex Pharmaceuticals Inc. announced a $10 billion cash acquisition of Crinetics Pharmaceuticals Inc. This significant transaction is poised to bolster Vertex's portfolio by expanding into the specialized field of endocrinology. The acquisition will introduce medicines targeting rare diseases like acromegaly and various other hormone-related disorders.
The terms of the agreement stipulate a purchase price of $85 per share for Crinetics' stock. This price reflects a substantial 102% premium over Crinetics' closing share price from the preceding day. The deal is expected to enhance Vertex's therapeutic offerings in critical areas of unmet medical need.
Through this acquisition, Vertex aims to leverage Crinetics' expertise and pipeline in endocrinology. The focus will be on developing and commercializing treatments for patients suffering from complex hormonal conditions. This strategic expansion underscores Vertex's commitment to growing its drug development capabilities and market presence.
